HELPHealthcare · Biotechnology

HELP Stock Forecast: Cybin, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$13

+1.08% on the day

The 10 Wall Street analysts covering Cybin, Inc. hold a median 12-month price target of $46 — +264.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 22 Aug 2026 — in the lower half.

Market cap

$919.8M

Ticker Nerd rank

41 / 100

Median analyst target

$46

Analysts covering

Total return, dividends reinvested

+5.1%

+55.6%

YTD

+54.1%

+82.2%

From 52W high

0.0%

From 52W low

+225.7%

$13

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

HELP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cybin, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

100

Accruals

Momentum

Issuance

Revisions

Volatility

Quality

Growth

Value

Size (100): Smaller than most of the companies we track.

Value (9): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HELP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HELP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts

10 Buy0 Hold0 Sell

Low $15Median $46High $71

The green dot is the last close — the median target sits +264.1% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
20 Aug 2026	TD Cowen	Maintains	Buy	$8.00 → $62
27 July 2026	Wells Fargo	Initiates	Overweight	—
27 July 2026	Wells Fargo	Initiates	Overweight	$16
9 July 2026	HC Wainwright & Co.	Maintains	Buy	$95 → $70
9 July 2026	HC Wainwright & Co.	Maintains	Buy	—
1 July 2026	Canaccord Genuity	Maintains	Buy	—
13 Apr 2026	TD Cowen	Initiates	Buy	—
2 Mar 2026	HC Wainwright & Co.	Maintains	Buy	—
3 Dec 2025	Guggenheim	Maintains	Buy	—
20 Nov 2025	Canaccord Genuity	Maintains	Buy	—
14 Nov 2025	HC Wainwright & Co.	Maintains	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HELP appears on the weeks it earns a place.

Estimates

HELP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Cybin, Inc. (HELP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −3.0×
Price / sales: —
Price / book: 235.0×
EV / EBITDA: −11.1×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −74.6%
Return on assets: −41.3%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

HELP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
HELPCybin, Inc.	$919.8M	41
BBLGBone Biologics Corp.	$1.7M	23
DCOYDecoy Therapeutics, Inc.	$2.1M	12
SLXNSilexion Therapeutics Corp.	$2.2M	53
CDTCDT Equity, Inc.	$2.3M	15
OGENOragenics, Inc.	$2.3M	10
VRAXVirax Biolabs Group Ltd.	$2.5M	13

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cybin, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HELP news & analysis

Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst

Seeking Alpha · 21 Aug 2026neutral

Helus Pharma, a psychedelic drug developer with a pipeline spanning MDD and GAD, has two clinical-stage assets and a serotonergic discovery platform. The company is running a phase III trial for its oral psilocin candidate, HLP003, which could validate its clinical profile and reduce its valuation discount versus peers.

Why it matters — As a competitor with a similar psychedelic pipeline approaching a pivotal phase III readout, Helus Pharma's progress is relevant context for Cybin (HELP) watchers tracking the psychedelic development landscape.

Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board

GlobeNewsWire · 18 Aug 2026positive

Helus Pharma announced the appointments of Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board. Both are former executives of Intra-Cellular Therapies, bringing experience in organizational scale-up, CNS drug development, regulatory approvals, and commercialization.

Why it matters — For Cybin (HELP) watchers, the addition of executives with CNS drug development and commercialization experience could strengthen leadership and advisory expertise in the CNS space.

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

GlobeNewsWire · 14 Aug 2026positive

Helus Pharma reported its first quarter fiscal 2027 financial results and recent business highlights. The company also announced the appointment of Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead it through late-stage development and commercialization.

Why it matters — The appointment of an experienced CEO with commercialization background signals leadership focus on advancing Helus Pharma through late-stage development, which is relevant to the Cybin (HELP) investment page.

Helus Pharma Appoints Michael Halstead as Chief Executive Officer

GlobeNewsWire · 3 Aug 2026neutral

Helus Pharma has appointed Michael Halstead as its new Chief Executive Officer. Halstead previously served as President of Intra-Cellular Therapies, a company that was later acquired by Johnson & Johnson.

Why it matters — The appointment of a CEO with experience scaling a company that was acquired by a major pharmaceutical firm could signal strategic leadership changes at Helus Pharma.

FAQ

Frequently asked questions about HELP stock

What is the HELP stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Cybin, Inc. have a median 12-month price target of $46, with estimates ranging from $15 to $71. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HELP stock a buy right now?

Of the 10 analysts covering Cybin, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cybin, Inc. 41 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HELP?

As at 22 Aug 2026, Cybin, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).

Will HELP stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +264.1% from the last close, and Ticker Nerd's factor model ranks Cybin, Inc. 41 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HELP stock forecast for 2030?

No analyst covering Cybin, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HELP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $71 over the next 12 months.

How has HELP stock performed over the past year?

Cybin, Inc. returned +82.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cybin, Inc. do?

Cybin Inc. is a clinical-stage neuropsychiatry company dedicated to developing psychedelic-based therapeutics to address unmet needs in mental health treatment.

What is the latest news on HELP?

The most recent item we track (Seeking Alpha, 21 Aug 2026): "Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst". Helus Pharma, a psychedelic drug developer with a pipeline spanning MDD and GAD, has two clinical-stage assets and a serotonergic discovery platform. The company is running a phase III trial for its oral psilocin candidate, HLP003, which could validate its clinical profile and reduce its valuation discount versus peers.

Company

About Cybin, Inc.

Cybin Inc. is a clinical-stage neuropsychiatry company dedicated to developing psychedelic-based therapeutics to address unmet needs in mental health treatment. Its lead candidate, CYB003, a proprietary deuterated psilocybin analog, is advancing in phase 3 clinical trials for major depressive disorder, including the multinational EMBRACE study approved in Australia and Europe. CYB004, a deuterated DMT molecule, is in phase 2 trials for generalized anxiety disorder, with enrollment recently completed. The pipeline also features investigational compounds like SPL028, an injectable deuterated DMT that completed phase 1 trials, SPL026 for MDD, and CYB005, a phenethylamine derivative in preclinical stages targeting neuroinflammation and central nervous system disorders. Headquartered in Toronto, Ontario, with approximately 50 employees, Cybin Inc. collaborates with partners such as TMS Neurohealth Centers, Kernel, and Segal Trials to advance its research. Founded in 2016 and led by CEO Eric So, the company plays a pioneering role in the emerging field of psychedelic medicine within the biopharmaceutical sector, focusing on innovative solutions for conditions like depression and anxiety.

CEO Mr. Eric So L.L.B. · 100 employees · Canada · https://www.helus.com